XORTX Therapeutics Inc. Files December 2024 Report
Ticker: XRTX · Form: 6-K · Filed: Dec 19, 2024 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, 6-K
TL;DR
XORTX filed a 6-K for Dec 2024, CEO signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on December 19, 2024, to report its activities for the month of December 2024. The company, headquartered in Calgary, Alberta, is a pharmaceutical preparations company. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides an update on the company's ongoing operations and regulatory compliance for the period. Investors can review this to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that reports on the company's activities for a specific period and does not contain new financial or operational material events.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- December 19, 2024 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of December 2024.
Who is the Chief Executive Officer of XORTX Therapeutics Inc. and who signed this report?
Allen Davidoff is the Chief Executive Officer of XORTX Therapeutics Inc., and he signed this report on behalf of the registrant.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on December 19, 2024.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Does XORTX Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
XORTX Therapeutics Inc. files annual reports under Form 20-F, as indicated by the checkmark in the filing.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-12-19 09:12:02
Filing Documents
- f6k_121924.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-24-007007.txt ( ) — 10KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: December 19, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated December 19, 2024